SCHEMBL5757855

SCHEMBL5757855

Cc1cccc(N/C=C/C=C(C(=O)O)C(=O)O)n1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.50
▸ KMT2A Q03164 5/20 0.50
▸ RAB9A P51151 5/20 0.49
▸ NPC1 O15118 4/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ GBA1 P04062 2/20 0.46
▸ GRM5 P41594 5/20 0.44
▸ SORT1 Q99523 1/20 0.42
▸ TP53 P04637 1/20 0.41
▸ FDPS P14324 1/20 0.40
▸ FDFT1 P37268 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5757860 1.00 MEN1 (0.50) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL11562497 0.72 MEN1 (0.87) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL5758373 0.72 MEN1 (0.50) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL5758370 0.72 MEN1 (0.50) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL1137151 0.71 NPC1 (0.50) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL4581966 0.71 KMT2A (0.57) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL1861757 0.70 RAB9A (0.55) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL31725239 0.70 RAB9A (0.78) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL11712255 0.70 RAB9A (0.55) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL3119185 0.70 RAB9A (0.78) MEN1KMT2ARAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 — — EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 — — US disclosed
EP-1562902-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE AstraZeneca AB (SE) 2005-08-17 — — EP disclosed
WO-2004043924-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 MEN1 3423/4885KMT2A 4487/4885RAB9A 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback